All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Details:
Oxford BioTherapeutics will validate five novel oncology drug targets, previously identified using OBT’s OGAP® discovery platform, and generate antibodies against these targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Humabody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration December 10, 2020
Details:
The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LentiVector based gene therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Oxford Biomedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2020
Details:
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APN431
Therapeutic Area: Oncology Product Name: APN431
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2020
Details:
Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $420.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration September 09, 2020
Details:
Under the terms of the collaboration agreement, Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): C0021158
Therapeutic Area: Oncology Product Name: C0021158
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
ARG2 targets and destroys L-arginine, an amino acid critical for immune cells to fight diseases such as cancer, as well as infections.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADP-c165
Therapeutic Area: Oncology Product Name: ADP-c165
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
Presentations highlight significant new data for key oncology drug development programmes - USP7 small molecule inhibitors and ROR1 Protein: Drug Conjugates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 17, 2020
Details:
The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb tocapitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2020
Details:
The new 3 years research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as part of the Vernalis Design Platform with the oncology expertise at Servier to enable to identify and enable new therapeutic targets.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
